Cytokinetics(CYTK)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CYTK Cytokinetics

未开盘 07-08 16:00:00 EDT

84.88

-0.68

-0.79%

盘后84.88

+0.000.00%

19:53 EDT

最高85.87	最低82.20	成交量237.75万
今开85.00	昨收85.56	日振幅4.29%
总市值115.44亿	流通市值114.59亿	总股本1.36亿
成交额2.00亿	换手率1.76%	流通股本1.35亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CYTK","market":"US","secType":"STK","nameCN":"Cytokinetics","latestPrice":84.88,"timestamp":1783540800000,"preClose":85.56,"halted":0,"volume":2377531,"hourTrading":{"tag":"盘后","latestPrice":84.88,"preClose":84.88,"latestTime":"19:53 EDT","volume":54052,"amount":4587926.2599,"timestamp":1783554781109,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.007947639083684043,"floatShares":135000000,"shares":136000000,"eps":-6.839943,"marketStatus":"未开盘","change":-0.68,"latestTime":"07-08 16:00:00 EDT","open":85,"high":85.87,"low":82.2,"amount":200080098.96667,"amplitude":0.042894,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-6.839943,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1783584000000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1083211200000,"exchange":"NASDAQ","adjPreClose":85.56,"preHourTrading":{"tag":"盘前","latestPrice":84.3421,"preClose":85.56,"latestTime":"09:27 EDT","volume":298,"amount":25338.751067999998,"timestamp":1783517269243,"change":-1.2179,"changeRate":-0.014234,"amplitude":0.018208},"postHourTrading":{"tag":"盘后","latestPrice":84.88,"preClose":84.88,"latestTime":"19:53 EDT","volume":54052,"amount":4587926.2599,"timestamp":1783554781109,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.069548,"impliedVol":0.5185,"impliedVolPercentile":0.1793},"requestUrl":"/m/hq/s/CYTK","defaultTab":"news","newsList":[{"id":"1128861683","title":"Cytokinetics公布三项欧洲心脏病学会2026年会最新突破性科学研究摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=1128861683","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128861683?lang=zh_cn&edition=full","pubTime":"2026-07-07 19:39","pubTimestamp":1783424373,"startTime":"0","endTime":"0","summary":"Cytokinetics公司宣布，将在2026年欧洲心脏病学会年会上展示三项最新突破性科学研究摘要。这一消息标志着该公司在心衰治疗领域的研究进展再次获得国际顶级学术会议的认可。欧洲心脏病学会年会是全球心血管领域规模最大、最具影响力的科学盛会之一，入选其最新突破性科学环节的研究通常代表了该领域的前沿发现与重要临床进展。此次公布的三项摘要内容预计将涉及Cytokinetics在心衰药物开发方面的最新数据与分析。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4505","CYTK","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115149489","title":"异动解读｜Cytokinetics盘中上涨5.17%，报79.1美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1115149489","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115149489?lang=zh_cn&edition=full","pubTime":"2026-06-18 00:25","pubTimestamp":1781713528,"startTime":"0","endTime":"0","summary":"6月17日，Cytokinetics盘中上涨5.17%，报79.1美元/股，成交额8931.1万美元。Cytokinetics所在的生物科技行业中，个股中，uniQure N.V.涨73.69%，艾伯维公司跌0.21%，吉利德科学跌0.3%，安进跌0.25%，Nuvalent, Inc.跌0.0%。Cytokinetics是一家处于临床阶段的生物制药公司，主要致力于发现和开发调节肌肉功能的新型小分子治疗方法，为重大疾病提供潜在治疗方案。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CYTK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172862671","title":"Cytokinetics在欧盟推出Myqorzo® (Aficamten)，德国率先实现商业化供应","url":"https://stock-news.laohu8.com/highlight/detail?id=1172862671","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172862671?lang=zh_cn&edition=full","pubTime":"2026-06-01 19:31","pubTimestamp":1780313471,"startTime":"0","endTime":"0","summary":"Cytokinetics公司宣布，其药物Myqorzo® (Aficamten) 现已在欧盟市场正式推出，首站商业供应落地德国。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","CYTK","BK4139","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157407399","title":"Cytokinetics宣布在德国推出Myqorzo (Aficamten)，用于治疗有症状的梗阻性肥厚型心肌病","url":"https://stock-news.laohu8.com/highlight/detail?id=1157407399","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157407399?lang=zh_cn&edition=full","pubTime":"2026-06-01 19:30","pubTimestamp":1780313418,"startTime":"0","endTime":"0","summary":"Cytokinetics公司宣布，其新药Myqorzo（通用名：Aficamten）现已在德国正式上市，该药物适用于治疗有症状的梗阻性肥厚型心肌病（oHCM）患者。\n这一商业化的推进，标志着该创新疗法在关键欧洲市场迈出了重要一步。Myqorzo是一种口服小分子心肌肌球蛋白抑制剂，旨在通过靶向心肌过度收缩的潜在机制来改善患者的心脏功能并缓解相关症状。其在德国的成功推出，为当地受此疾病困扰的患者提供了一个新的治疗选择。\n","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CYTK","BK4505","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152068979","title":"异动解读 | Cytokinetics盘中大涨5.64%，公开发行募资完成及关键III期试验达双重终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1152068979","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152068979?lang=zh_cn&edition=full","pubTime":"2026-05-09 00:15","pubTimestamp":1778256939,"startTime":"0","endTime":"0","summary":"Cytokinetics（股票代码：CYTK）今日盘中大涨5.64%，引起了市场的广泛关注。消息面上，公司近期完成了公开发行普通股的交割，此次发行募资总额达8.05亿美元，为公司后续的商业化进程及研发管线的推进提供了坚实的资金保障。此外，公司此前公布的心肌肌球蛋白抑制剂aficamten治疗非梗阻性肥厚型心肌病的关键III期ACACIA-HCM试验，达到了预设的双重主要终点，在临床评估中显示出统计学上的显著改善。值得注意的是，其竞品在同类适应症的试验中未能成功，这使得Cytokinetics在该领域取得了领先优势。这些积极进展增强了投资者对公司未来增长潜力的信心，共同推动了股价的显著上扬。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["CYTK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633417959","title":"美股异动 | 心脏病药物实验取得积极结果 Cytokinetics(CYTK.US)早盘暴涨超20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633417959","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633417959?lang=zh_cn&edition=full","pubTime":"2026-05-05 23:16","pubTimestamp":1777994180,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周二，Cytokinetics早盘暴涨超20%，创年内新高，现报79.72美元。消息面上，此前该公司宣布其关键的3期ACACIA-HCM试验取得了积极的初步结果，达到了两个主要终点。该试验评估了aficamten在有症状的非梗阻性肥厚型心肌病患者中的效果。这种心脏疾病的特点是心肌增厚导致呼吸急促、疲劳和胸痛等症状，但没有显著的血流阻塞。Cytokinetics报告称，ACACIA-HCM达到了双重主要终点，显示从基线到第36周有显著改善。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1438244.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"美股异动 | 心脏病药物实验取得积极结果 Cytokinetics(CYTK.US)早盘暴涨超20%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK4139","BK4505","BK4585","CYTK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122513115","title":"Cytokinetics公司未发现新的安全信号 Aficamten与安慰剂完成率相当","url":"https://stock-news.laohu8.com/highlight/detail?id=1122513115","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122513115?lang=zh_cn&edition=full","pubTime":"2026-05-05 19:31","pubTimestamp":1777980682,"startTime":"0","endTime":"0","summary":"Cytokinetics公司最新研究数据显示，其药物Aficamten在临床试验中未出现新的安全性问题。值得注意的是，接受Aficamten治疗的患者与使用安慰剂的患者在试验完成率方面表现出高度一致性。\n这一发现为Aficamten的后续开发提供了重要支持。研究人员指出，两组受试者均展现出良好的治疗依从性，这进一步印证了该药物的耐受性特征。目前，公司正在对详细数据进行深度分析，以评估该药物在特定患者群体中的潜在价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CYTK","BK4139","BK4505","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177106889","title":"Cytokinetics公布Acacia-HCM三期关键临床试验积极顶线结果：Aficamten治疗非梗阻性肥厚型心肌病疗效显著","url":"https://stock-news.laohu8.com/highlight/detail?id=1177106889","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177106889?lang=zh_cn&edition=full","pubTime":"2026-05-05 19:31","pubTimestamp":1777980679,"startTime":"0","endTime":"0","summary":"Cytokinetics宣布其针对非梗阻性肥厚型心肌病患者的创新药物Aficamten，在三期关键临床试验Acacia-HCM中取得突破性顶线结果。数据显示，该试验成功达到主要疗效终点，验证了Aficamten在改善患者运动能力与症状控制方面的卓越潜力。\n此次研究成果为肥厚型心肌病治疗领域注入新动力，标志着Cytokinetics在心脑血管疾病创新疗法开发中迈出关键一步。公司计划基于这些数据与全球监管机构展开深入沟通，加速推动Aficamten的上市进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","CYTK","BK4139","BK4588","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102489233","title":"Cytokinetics公司药物Acacia-HCM在第36周同时达到KCCQ-CSS与最大运动能力双主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1102489233","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102489233?lang=zh_cn&edition=full","pubTime":"2026-05-05 19:31","pubTimestamp":1777980677,"startTime":"0","endTime":"0","summary":"Cytokinetics公司宣布，其针对肥厚型心肌病（HCM）的研究性药物Acacia-HCM，在为期36周的关键临床试验中，成功达成了预设的双重主要疗效终点。该试验结果显示，与安慰剂组相比，接受Acacia-HCM治疗的患者在堪萨斯城心肌病问卷临床总结评分（KCCQ-CSS）和最大运动能力（通过心肺运动测试衡量）方面均表现出统计学显著和临床意义的改善。\n这一积极数据标志着Acacia-HCM在改善HCM患者生活质量和功能状态方面展现出巨大潜力，为后续向监管机构提交申请奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CYTK","BK4505","BK4585","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198453673","title":"异动解读 | Cytokinetics盘前大涨5.98%，关键三期临床试验顶线结果即将公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1198453673","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198453673?lang=zh_cn&edition=full","pubTime":"2026-05-05 16:31","pubTimestamp":1777969865,"startTime":"0","endTime":"0","summary":"Cytokinetics (CYTK) 今日盘前大涨5.98%，引起了市场的广泛关注。消息面上，公司宣布将于今日正式公布其核心药物Aficamten针对非梗阻性肥厚型心肌病患者开展的关键三期临床试验Acacia-HCM的顶线研究结果，市场对这一里程碑式的临床数据发布抱有积极预期。该试验结果将为这一创新疗法的疗效与安全性评估提供关键依据，此前常规交易时段，公司股价已有所上涨，显示出市场对临床数据公布的持续升温预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["CYTK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122543275","title":"Cytokinetics将于2026年5月5日公布Aficamten治疗非梗阻性肥厚型心肌病的关键三期临床试验Acacia-HCM的顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1122543275","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122543275?lang=zh_cn&edition=full","pubTime":"2026-05-05 04:00","pubTimestamp":1777924814,"startTime":"0","endTime":"0","summary":"Cytokinetics公司宣布，将于2026年5月5日正式公布其核心药物Aficamten针对非梗阻性肥厚型心肌病患者开展的关键三期临床试验——Acacia-HCM的顶线研究结果。这项里程碑式临床数据的发布，将为该创新疗法的疗效与安全性评估提供关键依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CYTK","BK4505","BK4585","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170792564","title":"Cytokinetics将在2026年欧洲心脏病学会心力衰竭大会上发表九项研究成果","url":"https://stock-news.laohu8.com/highlight/detail?id=1170792564","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170792564?lang=zh_cn&edition=full","pubTime":"2026-04-28 19:32","pubTimestamp":1777375945,"startTime":"0","endTime":"0","summary":"Cytokinetics公司近日宣布，其九项前沿研究获选将于2026年欧洲心脏病学会心力衰竭大会进行专题报告。这些报告将集中展示公司在心血管疾病治疗领域的最新突破性进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","BK4585","CYTK","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145232006","title":"财报前瞻｜Cytokinetics本季营收或增616.29%，机构看多为主","url":"https://stock-news.laohu8.com/highlight/detail?id=1145232006","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145232006?lang=zh_cn&edition=full","pubTime":"2026-04-28 11:31","pubTimestamp":1777347112,"startTime":"0","endTime":"0","summary":"Cytokinetics将于2026年05月05日（盘后）发布最新季度业绩，市场关注收入弹性与费用投放节奏对亏损幅度的影响。市场一致预期本季度Cytokinetics总营收为861.46万美元，同比+616.29%；调整后每股收益为-1.65美元，同比-19.59%；息税前利润为-1.92亿美元，同比-25.37%。从近期机构表态看，看多观点占主导。与此同时，多家机构汇总口径显示Cytokinetics的平均评级为“买入”、平均目标价为90.39美元，反映多数卖方认为公司在收入端的弹性与中期增长可见度具备支持。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Cytokinetics本季营收或增616.29%，机构看多为主","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CYTK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130058429","title":"Cytokinetics公布2026年财务指引：截至2025年末现金及投资总额达12亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1130058429","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130058429?lang=zh_cn&edition=full","pubTime":"2026-02-25 05:44","pubTimestamp":1771969477,"startTime":"0","endTime":"0","summary":"生物制药公司Cytokinetics近日披露了2026年度财务规划蓝图。最新数据显示，截至2025年12月31日，公司持有的现金、现金等价物及投资组合规模突破12亿美元大关。这一稳健的资金储备为后续心血管疾病创新疗法的研发与商业化注入强心剂。在资本市场的持续关注下，Cytokinetics将依托现有资金优势推进关键临床项目。随着心力衰竭治疗领域竞争白热化，Cytokinetics的现金流状况为其在专利博弈和市场拓展中提供了独特优势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4505","BK4139","CYTK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180684705","title":"Cytokinetics宣布欧盟委员会批准Myqorzo®（Aficamten）用于治疗成人症状性梗阻性肥厚型心肌病","url":"https://stock-news.laohu8.com/highlight/detail?id=1180684705","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180684705?lang=zh_cn&edition=full","pubTime":"2026-02-17 20:31","pubTimestamp":1771331475,"startTime":"0","endTime":"0","summary":"生物制药公司Cytokinetics宣布，其创新药物Myqorzo®（Aficamten）已获得欧盟委员会正式批准，适用于治疗成人症状性梗阻性肥厚型心肌病（HCM）。这一监管里程碑标志着该药物在欧洲市场取得重要进展，为患有此类心脏疾病的患者提供了新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","BK4585","CYTK","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136079223","title":"财报前瞻｜Cytokinetics本季营收或增296.84%，机构看多占优","url":"https://stock-news.laohu8.com/highlight/detail?id=1136079223","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136079223?lang=zh_cn&edition=full","pubTime":"2026-02-17 11:07","pubTimestamp":1771297664,"startTime":"0","endTime":"0","summary":"Cytokinetics将于2026年02月24日盘后公布最新季度业绩，市场普遍关注收入弹性与费用节奏下的盈利路径变化。基于市场一致预期，本季度Cytokinetics营收预计为691.13万美元，同比变动+296.84%；调整后每股收益预计为-1.46美元，同比变动-22.08%，息税前利润预计为-1.77亿美元，同比变动-25.66%；上季度财报未见对本季度毛利率、净利润或净利率的可量化指引，当前一致预期未显示相关数据。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Cytokinetics本季营收或增296.84%，机构看多占优","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CYTK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164613916","title":"Cytokinetics携手奥运冠军Sydney McLaughlin-Levrone 共同提升对肥厚型心肌病整体影响的认识","url":"https://stock-news.laohu8.com/highlight/detail?id=1164613916","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164613916?lang=zh_cn&edition=full","pubTime":"2026-01-27 21:01","pubTimestamp":1769518880,"startTime":"0","endTime":"0","summary":"生物制药企业Cytokinetics与奥运金牌得主Sydney McLaughlin-Levrone展开合作，旨在提高公众对肥厚型心肌病全方位影响的认识。此次合作将聚焦于揭示该疾病对患者生理、心理及生活质量的综合影响，打破仅关注单一症状的传统认知局限。作为拥有深厚心血管疾病研究背景的公司，Cytokinetics长期致力于创新疗法的开发。随着公众对HCM认知边界的拓展，未来有望推动更人性化的医疗方案诞生。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","CYTK","BK4139","BK4505","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162316069","title":"Cytokinetics宣布Myqorzo™（Aficamten）在美国上市，用于治疗成人症状性梗阻性肥厚型心肌病以改善功能能力和症状","url":"https://stock-news.laohu8.com/highlight/detail?id=1162316069","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162316069?lang=zh_cn&edition=full","pubTime":"2026-01-27 20:32","pubTimestamp":1769517123,"startTime":"0","endTime":"0","summary":"Cytokinetics公司宣布，其创新药物Myqorzo™（Aficamten）现已在美国市场正式推出。该药物专为成人症状性梗阻性肥厚型心肌病（HCM）患者设计，旨在显著提升患者的功能能力并有效缓解相关症状。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4585","BK4505","CYTK","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517301014","title":"Cytokinetics, Incorporated2024财年实现净利润-5.90亿美元，同比减少12.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517301014","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517301014?lang=zh_cn&edition=full","pubTime":"2025-03-08 00:00","pubTimestamp":1741363247,"startTime":"0","endTime":"0","summary":"3月8日，Cytokinetics, Incorporated公布财报，公告显示公司2024财年净利润为-5.90亿美元，同比减少12.17%；其中营业收入为18.47百万美元，同比增加145.29%，每股基本收益为-5.26美元。从资产负债表来看，Cytokinetics, Incorporated总负债15.37亿美元，其中短期债务30.50百万美元，资产负债比为0.92，流动比率为6.16。机构评级：截至2025年3月8日，当前有20家机构对Cytokinetics, Incorporated目标价做出预测，其中目标均价为79.30美元，其中最低目标价为60.00美元，最高目标价为120.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000202a2647f1e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000202a2647f1e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CYTK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516652859","title":"Cytokinetics, Incorporated盘中异动 下午盘股价大跌5.11%报43.65美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516652859","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516652859?lang=zh_cn&edition=full","pubTime":"2025-03-04 02:25","pubTimestamp":1741026329,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日02时25分，Cytokinetics, Incorporated股票出现异动，股价快速跳水5.11%。截至发稿，该股报43.65美元/股，成交量75.1047万股，换手率0.63%，振幅6.13%。Cytokinetics, Incorporated股票所在的生物技术行业中，整体涨幅为0.16%。Cytokinetics, Incorporated公司简介：细胞动力科技有限公司是一家生物技术公司，开发肌肉生物学驱动的治疗以肌肉功能降低、肌肉无力和疲劳为特征的疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304022529a25d8339&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304022529a25d8339&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4588","BK4139","CYTK","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cytokinetics.com;ir.cytokinetics.com","stockEarnings":[{"period":"1week","weight":-0.0045},{"period":"1month","weight":0.2501},{"period":"3month","weight":0.3141},{"period":"6month","weight":0.3579},{"period":"1year","weight":1.4782},{"period":"ytd","weight":0.3359}],"compareEarnings":[{"period":"1week","weight":-0.0005},{"period":"1month","weight":0.0084},{"period":"3month","weight":0.0963},{"period":"6month","weight":0.074},{"period":"1year","weight":0.2016},{"period":"ytd","weight":0.0931}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Cytokinetics, Incorporated于1997年8月5日成立，符合特拉华州的法律规定。它是一家处于临床阶段的生物制药公司，主要致力于为重大疾病和糟糕的医疗条件提供潜在的治疗方法的这样一种调节肌肉功能的新型小分子治疗方法的发现和发展。它目前处于发展阶段，着重于科研，开发药品筛选技术和融资。","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":0.002159},{"month":2,"riseRate":0.454545,"avgChangeRate":-0.023832},{"month":3,"riseRate":0.5,"avgChangeRate":-0.000279},{"month":4,"riseRate":0.590909,"avgChangeRate":0.014515},{"month":5,"riseRate":0.608696,"avgChangeRate":0.027623},{"month":6,"riseRate":0.434783,"avgChangeRate":0.004691},{"month":7,"riseRate":0.652174,"avgChangeRate":0.057575},{"month":8,"riseRate":0.636364,"avgChangeRate":0.040484},{"month":9,"riseRate":0.409091,"avgChangeRate":0.034179},{"month":10,"riseRate":0.318182,"avgChangeRate":-0.070805},{"month":11,"riseRate":0.5,"avgChangeRate":0.021311},{"month":12,"riseRate":0.454545,"avgChangeRate":0.096331}],"exchange":"NASDAQ","name":"Cytokinetics","nameEN":"Cytokinetics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Cytokinetics(CYTK)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Cytokinetics(CYTK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Cytokinetics,CYTK,Cytokinetics股票,Cytokinetics股票老虎,Cytokinetics股票老虎国际,Cytokinetics行情,Cytokinetics股票行情,Cytokinetics股价,Cytokinetics股市,Cytokinetics股票价格,Cytokinetics股票交易,Cytokinetics股票购买,Cytokinetics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Cytokinetics(CYTK)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Cytokinetics(CYTK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}